David Lubner is a seasoned finance executive with 30 years of experience in the life sciences industry. Mr. Lubner served as executive vice president and chief financial officer (CFO) of Ra Pharmaceuticals, acquired by UCB in 2020. Prior to that, he was CFO of Tetraphase Pharmaceuticals and was previously CFO of PharMetrics until it was acquired by IMS Health. He also held the CFO position at ProScript, where VELCADE^®, a therapy widely used for the treatment of multiple myeloma, was discovered.  Mr. Lubner currently serves on the boards of directors of Arcellx, Cargo Therapeutics, Dyne Therapeutics and Vor Biopharma as well as several private companies. He previously served on the board of directors of Nightstar Therapeutics, until it was acquired by Biogen, and Point Biopharma, until its acquisition by Eli Lilly & Company.  Mr. Lubner received his BS in business administration from Northeastern University and an MS in taxation from Bentley University.